Fresenius Kabi to Acquire Fenwal Holdings
By LabMedica International staff writers Posted on 02 Aug 2012 |
Fresenius Kabi (Bad Homburg, Germany) will acquire Fenwal Holdings, Inc., (Lake Zurich, IL, USA) a US-based provider of transfusion technology products for blood collection, separation, and processing from TPG (formally Texas Pacific Group) and Maverick Capital.
The acquisition marks another major step in Fresenius Kabi's previous statement that expanding its medical devices/transfusion technology segment is a priority. Fresenius Kabi will now become a global leader in transfusion technology.
The two companies' business activities complement each other: Fenwal holds a stable position in the market for automated blood collection devices, while Fresenius Kabi is a major supplier of blood bags and filters used for manual blood collection. Combining the two businesses will lead to a comprehensive product portfolio in transfusion medicine.
In addition, the acquisition will enhance Fresenius Kabi's geographical presence. Fenwal, headquartered in Lake Zurich (IL, USA) generates more than half its sales in the United States, where its infrastructure will serve as a platform for further growth opportunities for Fresenius Kabi. Conversely, Fresenius Kabi's international network will expand Fenwal's global product reach. Significant potential for revenue and cost synergies will be created.
In 2011, Fenwal had sales of USD 614 million with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of USD 90 million. The company runs a state-of-the-art R&D center and operates five manufacturing facilities.
Approximately 92 million whole blood donations are collected annually around the world. The transfusion technology market is mainly driven by demographic developments and the growing demand for products for automated blood component processing. In addition, the increasing demand in emerging markets will lead to further growth in this product segment.
Financial terms were not disclosed. The transaction will be financed initially from existing funds, whereas the enterprise value does not exceed the proceeds of the May 2012 capital increase.
Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care.
Related Links:
Fresenius Kabi
Fenwal Holdings, Inc.
The acquisition marks another major step in Fresenius Kabi's previous statement that expanding its medical devices/transfusion technology segment is a priority. Fresenius Kabi will now become a global leader in transfusion technology.
The two companies' business activities complement each other: Fenwal holds a stable position in the market for automated blood collection devices, while Fresenius Kabi is a major supplier of blood bags and filters used for manual blood collection. Combining the two businesses will lead to a comprehensive product portfolio in transfusion medicine.
In addition, the acquisition will enhance Fresenius Kabi's geographical presence. Fenwal, headquartered in Lake Zurich (IL, USA) generates more than half its sales in the United States, where its infrastructure will serve as a platform for further growth opportunities for Fresenius Kabi. Conversely, Fresenius Kabi's international network will expand Fenwal's global product reach. Significant potential for revenue and cost synergies will be created.
In 2011, Fenwal had sales of USD 614 million with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of USD 90 million. The company runs a state-of-the-art R&D center and operates five manufacturing facilities.
Approximately 92 million whole blood donations are collected annually around the world. The transfusion technology market is mainly driven by demographic developments and the growing demand for products for automated blood component processing. In addition, the increasing demand in emerging markets will lead to further growth in this product segment.
Financial terms were not disclosed. The transaction will be financed initially from existing funds, whereas the enterprise value does not exceed the proceeds of the May 2012 capital increase.
Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care.
Related Links:
Fresenius Kabi
Fenwal Holdings, Inc.
Latest Industry News
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus
- AMP Publishes Best Practice Guidance for Slice Testing Approach in Diagnostics